Lab Dept:

Anatomic Pathology

Test Name:


General Information

Lab Order Codes:



Philadelphia Chromosome Ph1; BCR/ABL1, Qualitative, Diagnostic Assay

CPT Codes:

81206 – BCR/ABL1 (t(9;22)), translocation analysis; major breakpoint, qualitative or quantitative 81207 – BCR/ABL1, minor breakpoint, qualitative or quantitative
81208 – BCR/ABL1, other breakpoint, qualitative or quantitative

Test Includes:

Detect the presence or absence of BCR/ABL mRNA. If positive, the fusion variant will be reported.


Test Indications:

Aids in the diagnostic workup for patients with high probability bcr/abl1-positive hematopoietic neoplasms, predominantly CML and ALL. When positive, the test identifies which mRNA fusion variant is present to guide selection of an appropriate monitoring assay. If a quantitative monitoring assay is not available for a rare fusion variant, this assay may be of some value for monitoring, as it is quite sensitive and can provide a positive or negative result.

Lab Testing Sections:

Anatomic Pathology – Sendouts

Referred to:

Mayo Medical Laboratories (MML Test: BADX)

Phone Numbers:

MIN Lab: 612-813-6280

STP Lab: 651-220-6550

Test Availability:

Daily, 24 hours

Turnaround Time:

Results are reported in 5-10 days

Special Instructions:

Complete and submit “Hematopathology Patient Information Sheet” with the specimen. Include the following information: patient’s name, referring (ordering) physician, specimen submitted & pertinent clinical history.


Specimen Type:

Whole blood or Bone marrow


Lavender top (EDTA) tube

Draw Volume:

4 mL (Minimum: 1 mL) blood
3 mL (Minimum: 1 mL) bone marrow

Processed Volume:

Same as Draw Volume


Routine venipuncture; Routine bone marrow collection. Gently invert tube to mix.

Special Processing:

Lab Staff: Do Not Centrifuge. Specimen should remain in the original collection container. Label specimen appropriately (blood or bone marrow).Store and ship refrigerated. Forward promptly and include Hematopathology Patient Information Sheet. Specimen must arrive at Mayo within 120 hours of collection.

Patient Preparation:


Sample Rejection:

Mislabeled or unlabeled specimens; specimens other than blood or bone marrow; gross hemolysis


Reference Range:

Interpretive report. A qualitative result is provided that indicates the presence or absence of BCR/ABL mRNA. When positive, the fusion variant is also reported.

Critical Values:



This test is only qualitative and should not be used for routine monitoring. Monitoring of most CML patients should be performed using Mayo test: BCRAB, BCR/ABL, p210 mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative Chronic Myelogenous Leukemia (CML). Monitoring of patients known to carry a p190 fusion should be performed using Mayo test: BA190, BCR/ABL, p190, Quantitative mRNA Detection, Reverse Transcription- PCR, Quantitative Monitoring Assay. If a patient is known to have a rare fusion variant that is not covered by 1 of these monitoring assays, contact Dr. He or Dr. Viswanatha at 800-533-1710 extension 6-5323 to discuss whether this qualitative assay can be used for monitoring.


Reverse Transcription-Polymerase Chain Reaction (RT-PCR), multiplex PCR (LightCycler 96)


Mayo Medical Laboratories May 2016


1/29/2013: CPT 2013 update
9/2/2015: Method update, previous PCR method included fluorescent bead array analysis (Luminex). Change from ABL to ABL1. Specimen stability extended, previously arrival within 72 hours. Updated specimen rejection.
5/19/16: Storage temp change, previously room temp.